The large shareholder in SLA who is utilising Solagran products including Reopren has increased order sizes, demand in New Zealand is strengthening as patients whose families have a history of alzheimers embrace the treatment. Few potential patients are ware of this treatment at this time.
Sales are at $3500 per course and increasing.
This information came from one of the purchasers.
DYOR
IMOO
The large shareholder in SLA who is utilising Solagran products...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $11.84M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.5¢ | $296 | 1.445K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13294 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 17933 | 2 |
View Market Depth
| Last trade - 14.57pm 12/09/2025 (20 minute delay) ? |
| SLA (ASX) Chart |